{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05014139",
            "orgStudyIdInfo": {
                "id": "SGN22E-004"
            },
            "secondaryIdInfos": [
                {
                    "id": "EV-104",
                    "type": "OTHER",
                    "domain": "Seagen, Inc."
                }
            ],
            "organization": {
                "fullName": "Astellas Pharma Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)",
            "officialTitle": "A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-of-intravesical-enfortumab-vedotin-for-treatment-of-patients-with-non-muscle-invasive-bladder-cancer-nmibc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-16",
            "studyFirstSubmitQcDate": "2021-08-16",
            "studyFirstPostDateStruct": {
                "date": "2021-08-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Astellas Pharma Global Development, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Seagen Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC).\n\nThis study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease.\n\nIn this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.",
            "detailedDescription": "The study will be comprised of 2 parts. The first part (dose escalation) will find the highest dose of enfortumab vedotin that does not cause unacceptable side effects in participants. The second part (dose expansion) will use the dose found in the first part to test how well the drug works.\n\nAll participants will receive enfortumab vedotin. Treatment on the study will occur during the induction and maintenance phases, and participants will enter a follow-up period after completion of the maintenance phase."
        },
        "conditionsModule": {
            "conditions": [
                "Urinary Bladder Neoplasms",
                "Carcinoma in Situ",
                "Carcinoma Transitional Cell",
                "Non-muscle Invasive Bladder Cancer",
                "NMIBC"
            ],
            "keywords": [
                "Bladder Cancer",
                "Urothelial Cancer",
                "Enfortumab vedotin",
                "PADCEV",
                "Pharmacokinetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 58,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Enfortumab vedotin: Dose escalation cohort",
                    "type": "EXPERIMENTAL",
                    "description": "During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.",
                    "interventionNames": [
                        "Drug: Enfortumab vedotin"
                    ]
                },
                {
                    "label": "Enfortumab vedotin: Dose expansion cohort",
                    "type": "EXPERIMENTAL",
                    "description": "During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.",
                    "interventionNames": [
                        "Drug: Enfortumab vedotin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Enfortumab vedotin",
                    "description": "Given into the bladder (intravesically)",
                    "armGroupLabels": [
                        "Enfortumab vedotin: Dose escalation cohort",
                        "Enfortumab vedotin: Dose expansion cohort"
                    ],
                    "otherNames": [
                        "PADCEV, ASG-22CE, ASG-22ME"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "Incidence of laboratory abnormalities",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "Incidence of dose limiting toxicities (DLTs)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Approximately 7 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK) of enfortumab vedotin: Area under the concentration-time curve (AUC)",
                    "description": "AUC will be recorded from the PK blood samples collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "PK of enfortumab vedotin: Maximum concentration (Cmax)",
                    "description": "Cmax will be recorded from the PK blood samples collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "PK of enfortumab vedotin: Time to maximum concentration concentration (tmax)",
                    "description": "Tmax will be recorded from the PK blood samples collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "PK of enfortumab vedotin: Apparent terminal half-life (t1/2)",
                    "description": "T1/2 will be recorded from the PK blood samples collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "PK of enfortumab vedotin: Trough concentration (Ctrough)",
                    "description": "Ctrough will be recorded from the PK blood samples collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "Incidence of antitherapeutic antibodies (ATAs) to enfortumab vedotin",
                    "description": "Blood samples for ATA analysis will be collected.",
                    "timeFrame": "Approximately 1 year"
                },
                {
                    "measure": "Complete response (CR) rate",
                    "description": "CR rate is defined as the proportion of subjects achieving CR.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Duration of CR",
                    "description": "The time from first documented CR to the first evidence of recurrence, progression, or death due to any cause.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Rate of cystectomy",
                    "description": "The proportion of subjects who subsequently undergo cystectomy.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Progression-free survival",
                    "description": "The time from start of study treatment to the first evidence of progression or death due to any cause.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Cystectomy-free survival",
                    "description": "The time from start of study treatment to cystectomy or death due to any cause.",
                    "timeFrame": "Up to 5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed, non-muscle invasive urothelial carcinoma with carcinoma in situ (CIS) (with or without papillary disease)\n* Predominant histologic component (\\>50 percent) must be urothelial (transitional cell) carcinoma\n* Participants must have high-risk Bacillus Calmette-Guerin (BCG) - unresponsive disease, defined as (where adequate BCG therapy is defined as one of the following: 5 of 6 doses of an initial induction course + at least 2 of 3 doses maintenance therapy or 5 of 6 doses of an initial induction course + at least 2 of 6 doses of a second induction course):\n\n  * Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.\n  * Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy, or\n  * T1 high-grade disease at the first evaluation following an induction BCG course (at least 5 or 6 doses)\n* Participant must be ineligible for or refusing a radical cystectomy\n* All visible papillary Ta/T1 tumors must be completely resected within 60 days prior to enrollment.\n* Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2.\n\nExclusion Criteria:\n\n* Current or prior history of muscle-invasive urothelial carcinoma or metastatic disease.\n* Nodal or metastatic disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) within 3 months prior to study treatment\n* Concomitant upper tract urothelial carcinoma as noted on CT or MRI urogram performed within 3 months prior to study treatment\n* Prior or concomitant urothelial carcinoma of the prostatic urethra within 6 months prior to study treatment\n* Participants with tumor-related hydronephrosis\n* Participant has received other systemic anticancer therapy including chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, and/or investigational agent within 4 weeks or intravesical therapy within 6 weeks of first dose of study treatment\n* Participant has had any prior radiation to the bladder for urothelial cancer",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Seagen, Inc. Trial Information Support",
                    "role": "CONTACT",
                    "phone": "866-333-7436",
                    "email": "clinicaltrials@seagen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janet Trowbridge, MD",
                    "affiliation": "Seagen Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Banner MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "UCLA Department of Medicine - Hematology & Oncology",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of California at San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94134",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Northwestern University-Feinberg School of Medicine",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Markey Cancer Center / University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40508",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "Johns Hopkins Medical Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Laura & Isaac Perlmutter Cancer Center at NYU Langone Health",
                    "status": "COMPLETED",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University Medical Center",
                    "status": "COMPLETED",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "James Cancer Hospital / Ohio State University",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43221",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Sidney Kimmel Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Erlanger Oncology and Hematology",
                    "status": "RECRUITING",
                    "city": "Chattanooga",
                    "state": "Tennessee",
                    "zip": "37403",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.04563,
                        "lon": -85.30968
                    }
                },
                {
                    "facility": "University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "MD Anderson",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Urology San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Site CA11001",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2C1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Site FR33002",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69003",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "Site FR33001",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75013",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Site FR33003",
                    "status": "RECRUITING",
                    "city": "Rennes",
                    "zip": "35000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.11198,
                        "lon": -1.67429
                    }
                },
                {
                    "facility": "Site DE49001",
                    "status": "RECRUITING",
                    "city": "Goettingen",
                    "zip": "37075",
                    "country": "Germany"
                },
                {
                    "facility": "Site DE49002",
                    "status": "RECRUITING",
                    "city": "T\u00fcbingen",
                    "zip": "72076",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.52266,
                        "lon": 9.05222
                    }
                },
                {
                    "facility": "Site ES34001",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08025",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Site ES34004",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Site ES34003",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08036",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Site ES34002",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Site UK44002",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "EC1A 7BE",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                },
                {
                    "id": "D000002278",
                    "term": "Carcinoma in Situ"
                },
                {
                    "id": "D000093284",
                    "term": "Non-Muscle Invasive Bladder Neoplasms"
                },
                {
                    "id": "D000002295",
                    "term": "Carcinoma, Transitional Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5535",
                    "name": "Carcinoma in Situ",
                    "asFound": "Carcinoma in Situ",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2976",
                    "name": "Non-Muscle Invasive Bladder Neoplasms",
                    "asFound": "Non-muscle Invasive Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "asFound": "Carcinoma Transitional Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        }
    },
    "hasResults": false
}